This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Exploring the Evolving Role of PARP Inhibition and Immunotherapy in Gynecological Cancers

Exploring the Evolving Role of PARP Inhibition and Immunotherapy in Gynecological Cancers

Format

Meeting Coverage

Time to Complete

90 minutes

Released

September 3, 2019

Expires

September 3, 2020
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM

Accredited Providers



The University of Texas MD Anderson Cancer Center

Commercial Supporter

This activity is supported by an educational grant from Tesaro, Inc.

Program Description

The recent introduction of poly-(ADP ribose)-polymerase (PARP) inhibitors, which exploit underlying DNA damage repair pathology, have largely shifted the ovarian cancer (OC) clinical landscape. These therapies now offer patients, who previously had little or no treatment options, a potentially life-prolonging therapy. Despite this, the need for better therapies for OC patients remain, as previous therapies have offered only minimal benefit. Further insights into the nuances of DNA damage repair and the specific deficiencies that contribute OC and endometrial cancer (EC) oncogenesis have resulted in identifying new treatments, including immune-checkpoint inhibitors, as well as unique and potentially synergistic therapy combinations. Treating patients with these drug classes within the gynecological cancer landscape represents a novel development about which oncology healthcare providers struggle to remain up-to-date.

The University of Texas MD Anderson Cancer Center and its educational partner, ASiM CE LLC, will provide this enduring material activity, which will feature animated video segments and leverage patient-focused content to facilitate learner interaction, and merge clinical decision-making with evidence-based concepts to provide memorable, relevant, and retainable learning encounters.

Peer-to-Peer Journal Club

This supplemental, downloadable Peer-to-Peer Journal Club features citations and summaries of key findings from clinical articles and abstracts related to PARP inhibition in the management of patients with OC and EC, along with discussion questions to consider, for yourself or as part of a Journal Club.

Goals

  • HCPs will display a foundational knowledge of underlying DNA damage repair pathologies in ovarian and endometrial cancer that provide rationale for PARPi and ICI as treatments. (Knowledge, Competence)
  • HCPS will better able to assess the most recent data on approved and investigational PARP inhibitor mono- and combination therapy for patients with ovarian cancer. (Knowledge, Competence)
  • HCPs will have improved awareness of the growing body of literature highlighting the clinical potential of ICIs, and other emerging therapies for endometrial cancer. (Knowledge, Competence)
  • HCPs will be better able to iterate realized and potential impact of PARP inhibitors and ICIs on treatment decision-making regarding biomarker assessment, individual risk-to-benefit profiles, and adverse event recognition and management. (Knowledge, Competence)

Intended Audience

This is a targeted activity is targeted to academic and community medical oncology healthcare providers, primarily physicians.

Educational Methods

Didactic Lecture, Case Study, Audience Response System, Pre-/Post-Test, Question/Answer Sessions.

Educational Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • EXPLAIN deficient DNA damage repair in ovarian and endometrial cancer and mechanisms by which PARP inhibitors and immune checkpoint inhibitors target this pathology (knowledge, competence)
  • REVIEW the efficacy, safety, and clinical utility of PARP inhibitor sequential and combination therapy in ovarian and endometrial cancer (knowledge, competence)
  • DESCRIBE clinical practice implication of PARP inhibitors and immune checkpoint inhibitors on genetic testing, patient selection, and adverse event management (knowledge, competence)

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The University of Texas MD Anderson Cancer Center designates this internet enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Certificates

Certificates awarding AMA PRA Category 1 CreditTM  or certificates documenting participation will be issued immediately to participants when an individual completes the post-test and evaluation.

Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.

Method of Participation

This activity will take approximately 90 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

The University of Texas MD Anderson Cancer Center Disclosure Policy for Program Chairs, Planning Committee Members, Teachers, or Authors and CME Activity Reviewers

The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer's relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.

The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all potential conflicts of interest prior to this activity. For information on this process, please contact the CME/Conference Management at 713/792-5357.

The following Faculty, Program Planning Committee Members, and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. No presentations will include discussion of investigational or off-label uses of a product.

Faculty

Robert L. Coleman, MD, FACOG, FACS (Course Director)
Professor and Ann Rife Cox Chair
Department of Gynecologic Oncology and Reproductive Medicine
Executive Director, Cancer Network
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Coleman discloses the following:
Grant or Research Support: AstraZeneca, Clovis Oncology, Genentech-Roche, Janssen, Merck;
Paid Consultant: AbbVie, Cell Medica, COR2ED, Geistlich, Genmab, MoreHealth, Takeda, Tesaro;
Speaker's Bureau/Honoraria: Banner MDACC, Medscape, OncLive, Physicians Education Resource, Research to Practice, Roche, Scripps Cancer Center, Targeted
Oncology;
Membership advisory board: Aravive Biologics, Inc., ArQule, AstraZeneca, Clovis Oncology, Cordgenics, Eisai Medical Research, Genentech, Inc., ImmunoGen, Merck, Mersana Therapeutics, Inc., Myriad, National Comprehensive Cancer Network, Novocure, OncoMed Pharmaceuticals, Inc., Tesaro.

Ritu Salani, MD, MBA
Associate Professor College of Medicine
Obstetrics and Gynecology
The Ohio State University
Columbus, Ohio

Dr. Salani discloses the following:
Speaker's Bureau: Genentech;
Membership on advisory committees or review panels, board membership, etc.: Clovis Oncology, Tesaro.

Planning Committee Members

Robert L. Coleman, MD, FACOG, FACS, discloses the following:
Grant or Research Support: AstraZeneca, Clovis Oncology, Genentech-Roche, Janssen, Merck;
Paid Consultant: AbbVie, Cell Medica, COR2ED, Geistlich, Genmab, MoreHealth, Takeda, Tesaro;
Speaker's Bureau/Honoraria: Banner MDACC, Medscape, OncLive, Physicians Education Resource, Research to Practice, Roche, Scripps Cancer Center, Targeted Oncology;
Membership advisory board: Aravive Biologics, Inc., ArQule, AstraZeneca, Clovis Oncology, Cordgenics, Eisai Medical Research, Genentech, Inc., ImmunoGen, Merck, Mersana Therapeutics, Inc., Myriad, National Comprehensive Cancer Network, Novocure, OncoMed Pharmaceuticals, Inc., Tesaro.

The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

Planning Committee Members
Mary Gabb, Tamara Greiner, Daniel Guinee

CME Activity Reviewers/Approvers
Diane C. Bodurka, MD, BS, MPH (approver); Jack Fu, MD; Peter Norman, MD; Brian R. Weston, MD

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated at the top of this page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

The following is an enduring symposium archive activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the enduring expert panel, and a CME postassessment and evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue